{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:54:19Z","timestamp":1787630059101,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2015.00258","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T01:02:14Z","timestamp":1447808534000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis"],"prefix":"10.3389","volume":"3","author":[{"given":"Lan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Sheng","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Xuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Jun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1681\/ASN.2006070771","article-title":"Metabolic bone disease in chronic kidney disease","volume":"18","author":"Martin","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"F253","DOI":"10.1152\/ajprenal.00302.2004","article-title":"The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism","volume":"288","author":"Rodriguez","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin","volume":"34","author":"Levin","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1525-139X.2006.00141.x","article-title":"Managing erythropoietin hyporesponsiveness","volume":"19","author":"Kwack","year":"2006","journal-title":"Semin Dial"},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000013563","article-title":"Hyperparathyroidism and anemia in renal failure","volume":"20","author":"Gallieni","year":"2000","journal-title":"Am J Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000044878","article-title":"Red blood cell osmotic fragility in chronically hemodialyzed patients","volume":"78","author":"Wu","year":"1998","journal-title":"Nephron"},{"issue":"4","key":"B8","first-page":"161","article-title":"Intensification of anaemia by secondary hyperparathyroidism in hemodialysis patients","volume":"14","author":"Baradaran","year":"2001","journal-title":"Med J Islam Acad Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/2230-8210.81939","article-title":"Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: a case-control study","volume":"15","author":"Sliem","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"key":"B10","first-page":"190","article-title":"Hyperparathyroidism, anaemia and erythropoietin: effects on systolic function of dialysis patients. Abstracts of 31 st Congress of European Renal Association\/European dialysis ND Transplantation Association, September 5-8, 1999 Madrid","volume":"14","author":"Trovato","year":"1999","journal-title":"Nephrol Dial Transpl"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1172\/JCI110154","article-title":"Effect of parathyroid hormone on erythropoiesis","volume":"67","author":"Meytes","year":"1981","journal-title":"J Clin Invest"},{"issue":"12","key":"B12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.7326\/0003-4819-111-12-992","article-title":"Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial","volume":"111","author":"Eschbach","year":"1989","journal-title":"Ann Intern Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"issue":"15\u20136","key":"B14","first-page":"18","article-title":"Should we keep hemoglobin levels as a viable outcome measure?","volume":"24","author":"Singh","year":"2010","journal-title":"Nephrol News Issues"},{"key":"B15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","article-title":"Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis","volume":"369","author":"Phrommintikul","year":"2007","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/ndt\/gfq573","article-title":"Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009","volume":"26","author":"Regidor","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/0192623313486317","article-title":"High hematocrit resulting from administration of erythropoiesis-stimulating agents is not fully predictive of mortality or toxicities in preclinical species","volume":"42","author":"Andrews","year":"2014","journal-title":"Toxicol Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"B19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"2 Suppl 1","key":"B20","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"B21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2004.08.005","article-title":"Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"44","author":"Pisoni","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B22","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"B23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/pds.3855","article-title":"Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model","volume":"24","author":"Suttorp","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/nep.12332","article-title":"Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines","volume":"19","author":"Hung","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1939-1676.2004.tb00139.x","article-title":"Clinical effi-cacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia","volume":"18","author":"Randolph","year":"2004","journal-title":"J Vet Intern Med"}],"container-title":["Frontiers in Public Health"],"original-title":[],"deposited":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T16:04:20Z","timestamp":1448985860000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fpubh.2015.00258\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,18]]},"references-count":25,"URL":"https:\/\/doi.org\/10.3389\/fpubh.2015.00258","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,18]]}}}